Robaxin: Advanced Muscle Relaxation for Acute Musculoskeletal Pain
| Product dosage: 500mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 10 | $4.00 | $40.03 (0%) | 🛒 Add to cart |
| 20 | $2.25 | $80.05 $45.03 (44%) | 🛒 Add to cart |
| 30 | $1.67 | $120.08 $50.03 (58%) | 🛒 Add to cart |
| 60 | $0.92 | $240.16 $55.04 (77%) | 🛒 Add to cart |
| 90 | $0.67 | $360.24 $60.04 (83%) | 🛒 Add to cart |
| 120 | $0.58 | $480.31 $70.05 (85%) | 🛒 Add to cart |
| 180 | $0.50 | $720.47 $90.06 (87%) | 🛒 Add to cart |
| 270 | $0.44 | $1080.71 $120.08 (89%) | 🛒 Add to cart |
| 360 | $0.42
Best per pill | $1440.94 $150.10 (90%) | 🛒 Add to cart |
Synonyms | |||
Robaxin (methocarbamol) is a centrally acting skeletal muscle relaxant indicated for the relief of discomfort associated with acute, painful musculoskeletal conditions. It is used as an adjunct to rest, physical therapy, and other measures for the relief of muscle spasm. The mechanism of action is not fully established but is believed to involve central nervous system depression, leading to muscle relaxation without directly affecting skeletal muscle fibers or the neuromuscular junction. Methocarbamol does not directly relax tense skeletal muscles in man. This product is available in both oral tablet and injectable forms, with the oral formulation being most common for outpatient management. It is typically prescribed for short-term use to address acute episodes rather than chronic conditions.
Features
- Contains methocarbamol as the active pharmaceutical ingredient
- Available in 500mg and 750mg oral tablet formulations
- Rapid onset of action with peak plasma concentrations within 1-2 hours
- Extensive hepatic metabolism with renal excretion of metabolites
- Compatible with adjunctive therapies including NSAIDs and physical modalities
- Minimal direct effect on neuromuscular junction or muscle contractility
Benefits
- Provides effective relief from acute muscle spasms and associated pain
- Facilitates improved range of motion and functional mobility
- Allows for more effective participation in physical therapy programs
- Reduces muscle stiffness and tension that interferes with daily activities
- Complements other pain management strategies without opioid mechanisms
- Supports faster recovery from musculoskeletal injuries when used appropriately
Common use
Robaxin is primarily indicated as an adjunct to rest, physical therapy, and other measures for the relief of discomfort associated with acute, painful musculoskeletal conditions. It is commonly prescribed for muscle spasms resulting from injuries such as strains, sprains, and muscle tears. Healthcare providers frequently recommend it for patients recovering from orthopedic procedures or experiencing acute back pain. The medication is particularly valuable in situations where muscle spasm significantly limits mobility or causes substantial discomfort. It is typically used during the acute phase of musculoskeletal conditions rather than for chronic management.
Dosage and direction
The recommended adult dosage of Robaxin is 1500mg four times daily for the first 48-72 hours of treatment. For severe conditions, 8 grams per day may be administered. Maintenance dosing is typically 4-4.5 grams daily divided into three or four doses. The tablets should be swallowed whole with a full glass of water and may be taken with or without food. Dosage should be individualized based on severity of symptoms and patient response. Treatment beyond two or three weeks is not recommended unless clearly necessary. For geriatric patients or those with hepatic impairment, dosage reduction may be necessary. The injectable form is reserved for hospital use and administered by healthcare professionals.
Precautions
Patients should be cautioned about performing activities requiring mental alertness such as operating machinery or driving while taking Robaxin, as it may cause drowsiness, dizziness, or blurred vision. Alcohol consumption should be avoided as it may enhance these effects. Use with caution in patients with renal or hepatic impairment, as metabolism and excretion may be affected. The drug contains FD&C Yellow No. 5 (tartrazine) which may cause allergic-type reactions in susceptible individuals. Patients should be monitored for signs of excessive sedation or cognitive impairment. Gradual tapering may be necessary when discontinuing after prolonged use to prevent withdrawal symptoms.
Contraindications
Robaxin is contraindicated in patients with known hypersensitivity to methocarbamol or any component of the formulation. It should not be used in patients with renal impairment severe enough to compromise drug elimination. The injectable form is contraindicated in patients with epilepsy or other seizure disorders. Concomitant use with other central nervous system depressants is generally contraindicated unless carefully monitored. The drug is not recommended during pregnancy unless clearly needed, and should be used with caution in breastfeeding women. Pediatric safety and effectiveness have not been established.
Possible side effect
Common side effects include dizziness, drowsiness, nausea, and blurred vision. Some patients may experience headache, fever, metallic taste, or mild gastrointestinal disturbances. Less frequently reported effects include allergic reactions, rash, pruritus, conjunctivitis with nasal congestion, and mild cognitive impairment. The injectable form may cause pain at the injection site, flushing, hypotension, or bradycardia. Serious but rare adverse effects include anaphylaxis, leukopenia, and syncope. Most side effects are dose-dependent and tend to diminish with continued therapy or dosage reduction.
Drug interaction
Robaxin may potentiate the effects of alcohol and other CNS depressants including benzodiazepines, opioids, sedative antihistamines, and barbiturates. Concurrent use with MAO inhibitors may enhance sedative effects. It may interfere with laboratory tests for 5-hydroxyindoleacetic acid (5-HIAA) and vanillylmandelic acid (VMA). The drug may enhance the neuromuscular blocking effects of tubocurarine and other neuromuscular blocking agents. Caution is advised when combining with other medications metabolized by hepatic enzymes. Pyridostigmine may antagonize the effects of methocarbamol.
Missed dose
If a dose is missed, it should be taken as soon as remembered unless it is almost time for the next scheduled dose. In that case, the missed dose should be skipped and the regular dosing schedule resumed. Patients should not double the dose to make up for a missed one. Consistent dosing is important for maintaining therapeutic effect, but occasional missed doses are unlikely to cause significant problems due to the drug’s relatively short half-life. Patients should contact their healthcare provider if multiple doses are missed or if they are uncertain about how to proceed.
Overdose
Symptoms of overdose may include nausea, vomiting, drowsiness, blurred vision, hypotonia, coma, and respiratory depression. Severe overdose may result in seizures and cardiac irregularities. Management involves gastric lavage or activated charcoal if ingestion was recent, along with supportive measures including maintenance of adequate respiratory function and cardiovascular support. There is no specific antidote for methocarbamol overdose. Hemodialysis may be considered in severe cases, though its effectiveness is not well established. Patients should seek immediate medical attention if overdose is suspected.
Storage
Store at controlled room temperature between 20°C to 25°C (68°F to 77°F). Protect from moisture and light. Keep in the original container with the lid tightly closed. Do not store in bathroom medicine cabinets where moisture may accumulate. Keep out of reach of children and pets. Do not use after the expiration date printed on the packaging. Properly discard any unused medication through drug take-back programs or according to FDA guidelines for safe disposal.
Disclaimer
This information is for educational purposes only and does not constitute medical advice. Individual responses to medication may vary. Patients should consult with a qualified healthcare professional before starting, stopping, or changing any medication regimen. The prescribing physician should be informed of all medical conditions and concurrent medications. This information is not exhaustive and does not replace the official prescribing information. In case of medical emergency, contact appropriate emergency services immediately.
Reviews
Clinical studies demonstrate Robaxin’s effectiveness in reducing muscle spasm and improving functional outcomes when used as part of a comprehensive treatment plan. Many healthcare providers report satisfactory results in managing acute musculoskeletal conditions, particularly when initiated early in the treatment course. Patients often describe significant relief from muscle stiffness and pain, though some report sedation as a limiting factor. The medication is generally well-tolerated when used as directed for appropriate indications. Long-term satisfaction data supports its role as a valuable adjunctive therapy in acute musculoskeletal care.